Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Chemotherapy-Related Adverse Events Add to Economic Burden in Metastatic Breast Cancer

TOP - October 2012 VOL 5, NO 7 published on November 13, 2012 in Breast Cancer
Caroline Helwick

Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology.

“In addition, an analysis of healthcare costs stratified by the number of AEs reported by patients showed a clear trend: the economic burden of AEs increases with the number of AEs reported,” she added.

The study is the first to assess costs associated with AEs that occur during treatment for MBC, she said.

Hurvitz led a study sponsored by Genentech that aimed to quantify the economic impact of AEs reported in patients with MBC receiving first- or second-line therapy with taxanes or capecitabine for at least 30 days per treatment episode. Patients were selected from the PharMetrics Integrated Database. The data elements included pharmacy and medical claims from more than 100 healthcare plans in the United States, covering more than 70 million lives between 2000 and 2010.

The eligible cohort included 3222 patients who used a taxane (docetaxel, paclitaxel) first-line (n = 1866), capecitabine first-line (n = 812), taxane second-line (n = 715), or capecitabine second-line (n = 369). Patients treated with both classes during the same episode were excluded. The AE list included almost 2 dozen possible AEs.

AEs were commonly seen in each of the 4 study cohorts. With taxanes, 94.6% of first-line patients and 94.4% of second-line patients experienced at least 1 event during treatment. With capecitabine, 83.7% and 84.0%, respectively, experienced at least 1 AE. Nausea/vomiting was the most common complication with either agent, Hurvitz reported.

In general, patients who experienced no AEs in the study were relatively younger and had fewer comorbidities at baseline.

Incremental Monthly Costs Associated With AEs
The incremental costs associated with chemotherapy-related complications were estimated by comparing the average costs between the cohorts with AEs and without AEs for the 4 treatment groups. The analysis revealed the following:

  • Taxanes first-line: AEs were associated with a 38.7% increase in monthly costs, over patients without AEs ($3547). These incremental costs were mainly driven by increased inpatient costs and other drug costs (other than chemotherapy).
  • Taxanes second-line: AEs were associated with a 69.5% increase in monthly costs ($5320). Incremental costs were mainly driven by incremental pharmacy costs for chemo­therapy and other drugs.
  • Capecitabine first-line: AEs were associated with a 9% increase in monthly costs ($4933). Incremen­tal costs were mainly driven by inpatient and outpatient costs.
  • Capecitabine second-line: AEs were associated with an 82.9% increase in monthly costs ($4933). Incre­men­tal costs were mainly driven by inpatient and outpatient costs.

Increasing AEs per Episode Led to Higher Costs
The more AEs per episode, the greater the cost of care, the analysis further found. For example, for taxane first-line therapy, the mean cost for a treatment without an AE episode was approximately $10,000, which rose to approximately $11,000 in the setting of 1 or 2 AEs and to almost $15,000 in the setting of more than 4 AEs.

For second-line capecitabine, treatment without an AE episode cost approximately $6000, but rose to approximately $14,000 in the setting of more than 4 AEs.

The average monthly costs per type of AE were highest for skin toxicity with taxanes and for constitutional symptoms with capecitabine, both approaching $16,000 on average.

Hurvitz cautioned that the study has limitations: cause-and-effect associations cannot be confirmed and the reported rates are restricted to duration of an episode of treatment and did not take into account complications occurring after treatment ended. It is also a retrospective observational study based on claims data, though this also has the advantage of being a valid, large sample-source of clinical practice data, she pointed out.

“Further research evaluating the clinical and economic consequences of chemotherapy-related AEs in a pro­spec­tive manner can further characterize the effects seen here,” she said.

Related Items
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Last modified: April 27, 2020